BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT – Get Free Report) dropped 5.4% during mid-day trading on Friday . The stock traded as low as $8.64 and last traded at $8.6150. Approximately 69,674 shares traded hands during trading, a decline of 79% from the average daily volume of 339,335 shares. The stock had previously closed at $9.11.
Analyst Upgrades and Downgrades
A number of brokerages have issued reports on BBOT. Canaccord Genuity Group began coverage on shares of BridgeBio Oncology Therapeutics in a report on Monday, May 11th. They issued a “buy” rating and a $23.00 price target on the stock. HC Wainwright boosted their price target on BridgeBio Oncology Therapeutics from $27.00 to $29.00 and gave the stock a “buy” rating in a research report on Friday, March 6th. Wall Street Zen downgraded shares of BridgeBio Oncology Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 16th. Finally, Stifel Nicolaus began coverage on shares of BridgeBio Oncology Therapeutics in a research note on Tuesday, February 10th. They issued a “buy” rating and a $23.00 target price on the stock. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $25.00.
Get Our Latest Stock Analysis on BBOT
BridgeBio Oncology Therapeutics Price Performance
BridgeBio Oncology Therapeutics (NASDAQ:BBOT – Get Free Report) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($526.11) earnings per share for the quarter. As a group, equities research analysts predict that BridgeBio Oncology Therapeutics, Inc will post -2.18 EPS for the current fiscal year.
Institutional Trading of BridgeBio Oncology Therapeutics
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BBOT. Geode Capital Management LLC increased its stake in shares of BridgeBio Oncology Therapeutics by 3.8% in the fourth quarter. Geode Capital Management LLC now owns 561,987 shares of the company’s stock worth $7,039,000 after purchasing an additional 20,385 shares in the last quarter. Goldman Sachs Group Inc. bought a new position in shares of BridgeBio Oncology Therapeutics during the fourth quarter worth $1,185,000. BIT Capital GmbH purchased a new position in BridgeBio Oncology Therapeutics in the 4th quarter worth about $313,000. CIBC Private Wealth Group LLC purchased a new position in BridgeBio Oncology Therapeutics in the 4th quarter worth about $63,000. Finally, Renaissance Technologies LLC purchased a new position in BridgeBio Oncology Therapeutics in the 4th quarter worth about $930,000. 54.89% of the stock is owned by hedge funds and other institutional investors.
BridgeBio Oncology Therapeutics Company Profile
BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need.
BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development.
Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here.
Featured Stories
- Five stocks we like better than BridgeBio Oncology Therapeutics
- SpaceX IPO: Opportunity? Or the Ultimate Hype Trade?
- CAVA Group’s Stock Looks Delicious After Strong Earnings
- Lowe’s Finds Support at $215 After Q1 Earnings Sell-Off
- Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook
Receive News & Ratings for BridgeBio Oncology Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BridgeBio Oncology Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
